

Active Studies
Updated June 2011

Year(s) Study Active	Name of Study	Sponsor	PI/Co-Investigators	Subject Accrual	Target Subject Accrual
COHORT STUDIES					
2010-present	Collaborative Study of the Measurement of Cellular Markers as an Index of Oxidative Stress in HIV Positive and HIV Negative Persons	Fogarty International Center/NIH	J. DeHovitz	50	50
2009-present	An International Observational Study to Characterize Adults who are Hospitalized with Complications of Influenza A - Pandemic H1N1 (H1N1v) INSIGHT H1N1 Hospitalization Study (FLU 003)	NIAID/NIH/INSIGHT	J. DeHovitz	1	15
2009-present	An International Observational Study to Characterize Adults with Influenza A - Pandemic H1N1 (H1N1v) INSIGHT H1N1 Outpatient Study (FLU 002)	NIAID/NIH/INSIGHT	J. DeHovitz	0	15
2008-present	The Manhattan HIV Brain Bank	Mt. Sinai Medical Center (NIH)	H. Crystal	29	50
2005-present	Substance Abuse and HIV: Genetics & Disease Progression	NIMH	H. Crystal	2020	2200
1994-present	Women's Interagency HIV Study (WIHS)	NIAID/NCI/NIDA	H. Minkoff	620	620
2007-present	Pediatric HIV/AIDS Cohort Study (PHACS)	NICHD/ NIAID	H. Mendez	160	200+
CLINICAL TRIALS					
To Open in 2011	Strategic Timing of AntiRetroviral Treatment (START) A Multicenter Study of the International Network for Strategic Initiatives in Global HIV Trials	University of Minnesota/NIAID/INSIGHT	J. DeHovitz		15
To Open in 2011	An Open-Label, Extension Safety Trial of Pregabalin in Subjects with Neuropathic Pain Associated with HIV Neuropathy	Pfizer	Y. Anziska		5
To Open in 2011	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial of Pregabalin versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy	Pfizer	Y. Anziska		5
2010-present	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (GS-US-236-0103).	Gilead	J. Ravishankar	1	8
2010- present	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (GS-US 236-0102)	Gilead	J. Ravishankar	3	8
2009-present	Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety And Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults	Gilead	J. Ravishankar	2	8
2004-present	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects	Pfizer	J. Ravishankar	3	3
2004-present	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced, Non CCR5-Tropic HIV-1 Infected Subjects	Pfizer	J. Ravishankar	1	3
OTHER CLINICAL RESEARCH PROJECTS					
2008-present	Retention in Care	Centers for Disease Control and Prevention	T. Wilson	300	300
2008-present	African American Heterosexual HIV Risk Reduction	Centers for Disease Control and Prevention	T. Wilson	164	244